Advances in the treatment of acute heart failure.
Posted by giorgiobertin on April 27, 2024
A multicenter study conducted by Vanderbilt University Medical Center (VUMC) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure, a leading cause of hospitalization and death.
The drug, dapagliflozin, was initially approved to treat type 2 diabetes, but has since been shown to reduce the risk of hospitalization for heart failure and death in patients with serious health problems that include chronic heart and kidney disease and a high cardiovascular risk.
In an article published this month on the Journal of American College of Cardiology , researchers found that dapagliflozin also benefits patients after hospitalization for acute heart failure. The drug improves diuresis, or the elimination of excess fluid from the lungs, thus relieving congestion, and can reduce hospital stays.
Read abstract of the article:
Zachary L. Cox, Sean P. Collins, Gabriel A. Hernandez, A. Thomas McRae, Beth T. Davidson, Kirkwood Adams, Mark Aaron, Luke Cunningham, Cathy A. Jenkins, Christopher J. Lindsell, Frank E. Harrell, Christina Kampe, Karen F. Miller, William B. Stubblefield, JoAnn Lindenfeld. Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure. Journal of the American College of Cardiology2024; 83 (14): 1295 DOI: 10.1016/j.jacc.2024.02.009
Source: Vanderbilt University Medical Center (VUMC)
This entry was posted on aprile 27, 2024 a 6:15 am and is filed under News-research. Tagged: cardiology, pharmacology. You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a responseor trackback from your own site.